Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2021

View Archived Issues

Immunome establishes partnership to advance IMM-BCP-01 for COVID-19

"Inceptor" is new diabetes target

Corvus initiates phase III study of CPI-006 hospitalized patients with COVID-19

4D pharma provides updates for its lead immune-oncology candidate, MRx-0518

New Aurora kinase inhibitors described by Wigen Biomedicine Technology

Abbisko Therapeutics identifies new PD-1/PD-L1 interaction inhibitors

Huaxiasheng Pharmaceutical patents AChE and NO production inhibitors

New NMT inhibitors discovered at CSPC Zhongqi Pharmaceutical Technology

Staidson (Beijing) Biopharmaceuticals patents antibodies targeting Pseudomonas PcrV

SSTR2 is highly expressed in thymic epithelial tumors

Positive preliminary phase I data for iNKT cell therapy in patients with COVID1-9

FDA clears IND application for INT-301 oral mucosal immunotherapy

Crinetics' lead candidate CRN-04894 enters phase I development

New research suggests COVID-19 antibodies persist at least 6 months

University of South Australia discovers new candidate for glioblastoma

Thapsigargin shows broad-spectrum activity against respiratory viruses including SARS-CoV-2

New U.K. trial explores alternating different COVID-19 vaccines

HIV and AMD

TQB-2450, alone or with anlotinib, shows safety and efficacy in previously-treated NSCLC

Zydus Cadila completes phase I trials with antimalarial ZY-19489

CEACAM7 is a therapeutic target for CART therapy in PDAC

Clinical study provides proof of principle for HIV vaccine candidate eOD-GT8 60mer

China NMPA approves phase III trial of orelabrutinib with R-CHOP for MCL

Phase II study of SHR-0302 in ulcerative colitis meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...